Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

NCT03499353 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
61
Enrollment
INDUSTRY
Sponsor class

Stopped This study was terminated based on Pfizer's change in clinical development strategy not related to safety and efficacy.

Conditions

Interventions

Sponsor

Pfizer